.ALPHA.-1 PROTEASE INHIBITOR
Chronic Obstructive Pulmonary Disease
Takedaprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Chronic Obstructive Pulmonary Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Roflumilast Prince of Songkla University | Phase 3 | BB |
Sildenafil Rabin Medical Center | Phase 4 | B |
Tocilizumab Emory University | Phase 3 | B |
VILANTEROL Samsung Medical Center | Phase 3 | B |
UMECLIDINIUM Samsung Medical Center | Phase 3 | B |
View all 23 →
Same molecule, other indications
.ALPHA.-1 PROTEASE INHIBITOR is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →